Walleye Capital’s Kymera Therapeutics KYMR Stock Holding History

Walleye Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,181	Closed	-$1.49M	–	4691
2025 Q4	$1.49M	Buy	+19,181	New	+$1.3M	﹤0.01%	2104
2025 Q2	–	Sell	-10,059	Closed	-$275K	–	4801
2025 Q1	$275K	Buy	+10,059	New	+$367K	﹤0.01%	3022
2024 Q4	–	Sell	-9,976	Closed	-$472K	–	5220
2024 Q3	$472K	Buy	+9,976	New	+$441K	﹤0.01%	3343
2023 Q2	–	Sell	-15,524	Closed	-$460K	–	4610
2023 Q1	$460K	Sell	15,524 -36,804	-70%	-$1.19M	0.01%	1791
2022 Q4	$1.31M	Buy	+52,328	New	+$1.4M	0.02%	826
2021 Q2	–	Sell	-6,575	Closed	-$256K	–	1438
2021 Q1	$256K	Buy	+6,575	New	+$396K	0.01%	830

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Walleye Capital's KYMR Position: Q1 2026 in Review

Walleye Capital sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 19,181 shares — an estimated $1.49M sold.

Walleye Capital first reported a position in KYMR in Q1 2021 and held it in 6 quarters. The position peaked at $1.49M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Walleye Capital reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 19,181 Kymera Therapeutics shares in Q1 2026, an estimated $1.49M.
Walleye Capital first reported a position in Kymera Therapeutics in Q1 2021 and held it in 6 quarters.
Walleye Capital's Kymera Therapeutics position peaked at $1.49M in Q4 2025.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.